LONDON–(BUSINESS WIRE)– Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Eurozone AlphaDEX UCITS ETF 28.10.2026 FEUZ IE00B8X9NY41 1,606,130.00 EUR 102,223,384.00 63.646
Author: sHq_LoGiNz
LONDON–(BUSINESS WIRE)– Australia and New Zealand Banking Group Issue of GBP 105,000,000 Floating Rate Notes due July 2027 Series No 2208 Tranche No 1 MTN ISSUE NAME. Our Ref. MX3159 ISIN Code. XS3434472646 INTEREST AMT PER DENOM. CURRENCY CODE. GBP DAY BASIS. ACTUAL/365 FIXED (A005) NUM OF DAYS. 116 INTEREST RATE. 4.13305 PCT VALUE DATE. 30/10/2026 INTEREST PERIOD. 06/07/2026 TO 30/10/2026 GBP 100,000.00 IS GBP 1,313.52 POOL FACTOR. N/A
NEW YORK–(BUSINESS WIRE)–Enhanced Group Inc. (NYSE: ENHA) (“Enhanced” or the “Company”) today announced that its previously announced 1-for-10 reverse stock split of its Class A and Class B common stock (the “Reverse Stock Split”) has gone effective. Enhanced’s Class A common stock will begin trading on a split-adjusted basis when the market opens today, October 29, 2026, under the existing ticker symbol “ENHA.” The Class A common stock will trade under a new CUSIP number, 29333R206. As a res
NEW YORK–(BUSINESS WIRE)–InTandem Capital Partners, LP (“InTandem”), a healthcare-focused private equity firm, announced today that it has completed a strategic growth investment in Atlas Health (“Atlas” or the “Company”), an industry-leading AI-powered platform for patient affordability. The Atlas Health management team will continue to lead the Company and remain significant shareholders alongside InTandem. Founded in 2017, Atlas Health partners with hospitals and health systems to match an
WILLOW PARK, Texas–(BUSINESS WIRE)–ProFrac Holding Corp. (NASDAQ: ACDC) (“ProFrac” or the “Company”) announced today that it will report its third quarter 2026 financial results prior to the Company’s conference call, which will be webcasted on Thursday, November 5, 2026, at 8:30 a.m. Eastern / 7:30 a.m. Central. To register for and access the event, please click here. An archive of the webcast will be available shortly after the call’s conclusion on the IR Calendar section of ProFrac’s inves
AUBURN HILLS, Mich.–(BUSINESS WIRE)–PHINIA Inc. (NYSE: PHIN), (“PHINIA”, or the “Company”), a diversified industrial supplier and global leader in the development of fuel systems, electrical systems, and aftermarket solutions, today reported results for the third quarter ended September 30, 2026. THIRD QUARTER 2026 HIGHLIGHTS: (all comparisons versus the prior-year period) Net sales increased 0.4% to $912 million; excluding the impact of foreign currency, net sales remained flat year over yea
FAIRPORT, N.Y.–(BUSINESS WIRE)–Monro, Inc. (Nasdaq: MNRO), a leading provider of automotive repair and tire services, today announced financial results for its second quarter ended September 26, 2026. Second Quarter Results Sales for the second quarter of the fiscal year ending March 27, 2027 (“fiscal 2027”) decreased 1.8% to $283.6 million, as compared to sales of $288.9 million for the second quarter of the fiscal year ended March 28, 2026 (“fiscal 2026”). This was entirely driven by a 1.8%
TORONTO–(BUSINESS WIRE)—- $NPTH–NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), operates one of Canada’s largest networks of community-based, multidisciplinary medical facilities focused on the assessment and treatment of chronic pain, musculoskeletal/back pain, sports medicine and other pain-related medical services, today announced it will release its interim financial results for the three and nine months ended September 30, 2026 before markets open on Thursday, November 12, 2026. I
BOSTON–(BUSINESS WIRE)–Acadian Asset Management Inc. (NYSE: AAMI) today announced its results for the third quarter ended September 30, 2026. Acadian Asset Management Inc.’s earnings presentation is available at: ir.acadian-inc.com The Company will hold a conference call and simultaneous webcast to discuss the results at 11:00 a.m. Eastern Time today. To listen to the call or view the webcast, participants should: Dial-in Local Dial-in Number: (585) 542-9983 Toll Free Dial-in Number: (833)
SAN CARLOS, Calif.–(BUSINESS WIRE)–Dren Bio, a privately held, clinical-stage biotechnology company developing first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases, today announced the closing of an oversubscribed $350 million private financing. The round was co-led by Juvia Group and Lightspeed Venture Partners, with participation from an expanded syndicate of new investors including Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Managem